Organon & Co.
For the period ended Dec 31, 2024. Filed Feb 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 28, 2025
OGN$13.89+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income
($ in millions except shares in thousands and per share amounts)
| Year EndedDecember 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Revenues | $6,403 | $6,263 | $6,174 |
| Cost of sales | 2,688 | 2,515 | 2,294 |
| Gross profit | 3,715 | 3,748 | 3,880 |
| Selling, general and administrative | 1,760 | 1,893 | 1,704 |
| Research and development | 469 | 528 | 471 |
| Acquired in-process research and development and milestones | 81 | 8 | 107 |
| Restructuring costs | 31 | 62 | 28 |
| Interest expense | 520 | 527 | 422 |
| Exchange losses | 26 | 42 | 11 |
| Other expense, net | 21 | 15 | 15 |
| Income before income taxes | 807 | 673 | 1,122 |
| Income tax (benefit) expense | (57) | (350) | 205 |
| Net income | $864 | $1,023 | $917 |
| Earnings per share: | |||
| Basic | $3.36 | $4.01 | $3.61 |
| Diluted | $3.33 | $3.99 | $3.59 |
| Weighted average shares outstanding: | |||
| Basic | 257,046 | 255,239 | 254,082 |
| Diluted | 259,152 | 256,270 | 255,169 |
-57-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.